Drug Delivery to the CNS and Polymeric Nanoparticulate Carriers

• Calabria AR , ShustaEV. Blood–brain barrier genomics and proteomics: elucidating phenotype, identifying disease targets and enabling brain drug delivery.Drug Discov. Today11, 792–799 (2006).
   PubMedGoogle Scholar
• Pardridge WM . Blood–brain barrier delivery.Drug Discov. Today12, 54–61 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia E , AndrieuxK, GilS, CouvreurP. Colloidal carriers and blood–brain translocation: a way to deliver drugs to the brain?Int. J. Pharm.298, 274–292 (2005).
   PubMed Web of Science ®Google Scholar
• Lampson LA . Targeted therapy for neuro-oncology: reviewing the menu.Drug Discov. Today14, 185–191 (2009).
   PubMed Web of Science ®Google Scholar
• Stenehjem DD , HartzAMS, BauerB, AndersonGW. Novel and emerging strategies in drug delivery for overcoming the blood–brain barrier.Fut. Med. Chem.1, 1623–1641 (2009).
   PubMed Web of Science ®Google Scholar
• Hitchcock SA , PenningtonLD. Structure-brain exposure relationships.J. Med. Chem.49, 7559–7583 (2006).
   PubMed Web of Science ®Google Scholar
• Prokai-Tatrai K , ProkaiL. Modifying peptide properties by prodrug design for enhanced transport into the CNS. In: Peptide Transport and Delivery Into the Central Nervous System. Prokai-Tatrai K, Prokai L (Eds.). Birkhauser-Verlag, Basel, Switzerland, 155–188 (2003).
   Google Scholar
• Kerns EH , DiL. Chapter 10. In: Drug-like Properties: Concepts, Structure Design and Methods. Academic Press 122–136 (2008).
   Google Scholar
• Reichel A . Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.Chem. Biodiversity6, 2030–2049 (2009).
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M , FridenM, SyvanenS, GuptaA. On the rate and extent of drug delivery to the brain.Pharm. Res.25, 1737–1750 (2008).
   PubMed Web of Science ®Google Scholar
• Jones AR , ShustaEV. Blood–brain barrier transport of therapeutics via receptor mediation.Pharm. Res.24, 1759–1771 (2007).
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L . The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles?Drug Discov. Today13, 1099–1106 (2008).
   PubMed Web of Science ®Google Scholar
• Kumagai AK , EisenbergWM, PardridgeWM. Absorptive-mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood–brain barrier transport.J. Biol. Chem.262, 15214–15219 (1987).
   PubMed Web of Science ®Google Scholar
• Trigueiro D , BuciakJB, PardridgeWM. Capillary depletion method for quantifying blood–brain barrier transcytosis of circulating peptides and plasma proteins.J. Neurochem.54, 1882–1888 (1990).
   PubMedGoogle Scholar
• Bickel U , YoshikawaT, PardridgeWM. Delivery of peptides and proteins through the blood–brain barrier.Adv. Drug Del. Rev.46, 247–279 (2001).
   PubMed Web of Science ®Google Scholar
• Lee HJ , PardridgeWM. Pharmacokinetics and delivery of Tat and Tat-protein conjugates to tissues in vivo. Bioconj. Chem.12, 995–999 (2001).
   PubMed Web of Science ®Google Scholar
• Zorko M , LangelU. Cell-penetrating peptides: mechanism and kinetics of cargo delivery.Adv. Drug Del. Rev.57, 529–545 (2005).
   PubMed Web of Science ®Google Scholar
• DeBoer AG , GaillardPJ. Strategies to improve drug delivery across the blood–brain barrier.Clin. Pharmacokinet.46, 553–576 (2007).
   PubMed Web of Science ®Google Scholar
• Rousselle C . New advances in the transport of doxorubicin through the blood–brain barrier by a peptide vector-mediated strategy.Mol. Pharmacol.57, 679–686 (2000).
   PubMed Web of Science ®Google Scholar
• Rousselle C , ClairP, SmirnovaMet al. Improved brain uptake and pharmacological activity of dalargin using a peptide vector mediated strategy. J. Pharmacol. Exp. Ther. 306, 371–376 (2003).
   PubMed Web of Science ®Google Scholar
• Malakoutikhah M , TeixidoM, GiraltE. Toward an optimal blood–brain barrier shuttle by synthesis and evaluation of peptide libraries.J. Med. Chem.51, 4881–4889 (2008).
   PubMedGoogle Scholar
• Malakoutikhah M , PradesR, TeixidoM, GiraltE. N-methyl phenylalanine-rich peptides as highly versatile blood–brain barrier shuttles. J. Med. Chem.2354–2363 (2010).
   PubMedGoogle Scholar
• Gabathuler R . Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases.Neurobiol. Disease37, 48–57 (2010).
   PubMed Web of Science ®Google Scholar
• van Rooy I , Cakir-TasciogluS, CouraudPOet al. Identification of peptide ligands for targeting to the blood–brain barrier. Pharm. Res. 27, 673–682 (2010).
   PubMed Web of Science ®Google Scholar
• Gan CW , FengSS. Transferrin-conjugated nanoparticles of poly(lactide)-D-α-tocopheryl. polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood–brain barrier. Biomaterials31(30), 7748–7757 (2010).
   PubMed Web of Science ®Google Scholar
• Kumar P , WuHQ, JodiLMet al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39–43 (2007).
   PubMed Web of Science ®Google Scholar
• Pan W , KastinAJ, ZankelTC, van Kerkhof P, Terasaki T, Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood–brain barrie. J. Cell Sci.117, 5071–5078 (2004).
   PubMed Web of Science ®Google Scholar
• Prince WS , CormickLM, WendtDJet al. Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusion between the receptor-associated protein (RAP) and α-iduronidase or acid α-glucosidase. J. Biol. Chem. 279, 35037–35046 (2004).
   PubMed Web of Science ®Google Scholar
• Demeule M , ReginaA, CheCet al. Identification and design of peptides as new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324, 1064–1072 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas FC , TaskarK, RudrarajuVet al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood–brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26, 2486–2494 (2009).
   PubMed Web of Science ®Google Scholar
• Regina A , DemeuleM, CheCet al. Anti-tumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155, 185–197 (2008).
   PubMed Web of Science ®Google Scholar
• Drappatz J , BrennerA, RosenfeldSet al. Ang-1005: new EPiC compound for the treatment of recurrent malignant glioma. Presentated at: The EORTC-NCI-AACR Annual Meeting 2009, Boston, MA, USA, 15–19 November, 2009.
   Google Scholar
• Che C , YangG, ThiotCet al. New angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem. 53, 2814–2824 (2010).
   PubMed Web of Science ®Google Scholar
• Esfand R , TomaliaDA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications.Drug Discov. Today6, 427–436 (2001).
   PubMed Web of Science ®Google Scholar
• Medina SH , El-SayedEH. Dendrimers as carriers for delivery of chemotherapeutic agents.Chem. Rev.109, 3141–3157 (2009).
   PubMed Web of Science ®Google Scholar
• Astruc D , BoisselierE, OrnelasC. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine.Chem. Rev.110, 1857–1959 (2010).
   PubMed Web of Science ®Google Scholar
• Nanjwade BK , BechraHM, DerkarGK, ManviFV, NanjwadeVK. Dendrimers: emerging polymers for drug-delivery systems.Eur. J. Pharm. Sci.38, 185–196 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang L , GuF, ChanJM, WangAZ, LangerRS, FarokhzadOC. Nanoparticles in medicine: therapeutic applications and developments.Clin. Pharmacol. Ther.83, 761–769 (2008).
   PubMed Web of Science ®Google Scholar
• Ke W , ShaoK, HuangRet al. Gene delivery targeted to the brain using an angiopep- conjugated polyethyleneglycol-modified polyamidoamine dendrimers. Biomaterials 30, 6976–6985 (2009).
   PubMed Web of Science ®Google Scholar
• Huang RQ , KeWL, LiuY, ChenJ, PeiYY. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain.Biomaterials29, 238–246 (2008).
   PubMed Web of Science ®Google Scholar
• Liu Y , HuangR, HanLet al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30, 4195–4202 (2009).
   PubMed Web of Science ®Google Scholar
• Farokhzad OC , LangerR. Impact of nanotechnology on drug delivery.ACS Nano3, 16–20 (2009).
   PubMed Web of Science ®Google Scholar
• Huang G , ZhangN, BiX, DouM. Solid lipid nanoparticles of temozolomide: potential reduction of cardiac and nephric toxicity.Int. J. Pharm.355, 314–320 (2008).
   PubMed Web of Science ®Google Scholar
• Kaur IP , BhandariR, BhandariS, KakkarV, Potential of solid-lipid nanoparticles in brain targeting. J. Contr. Rel.127, 97–109 (2007).
   Google Scholar
• Joshi MD , MullerRH. Lipid nanoparticles for parenteral delivery of actives.Eur. J. Pharm. Biopharm.71, 161–172 (2009).
   PubMed Web of Science ®Google Scholar
• Costantino L , TosiG, RuoziB, BondioliL, VandelliMA, ForniF. Colloidal systems for CNS drug delivery.Progr. Brain Res.180, 35–69 (2009).
   PubMed Web of Science ®Google Scholar
• Saad M , GarbuzenkoOB, BerEet al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J. Contr. Rel. 130, 107–114 (2008).
   PubMed Web of Science ®Google Scholar
• Tosi G , CostantinoL, RuoziB, ForniF, VandelliMA. Polymeric nanoparticles for the drug delivery to the central nervous system.Exp. Opin. Drug Del.5, 155–174 (2008).
   PubMed Web of Science ®Google Scholar
• Owens DE , PeppasNA. Opsonization, biodistribution and pharmacokinetics of polymeric nanoparticles.Int. J. Pharm.307, 93–102 (2006).
   PubMed Web of Science ®Google Scholar
• Moghimi SM , SzebeniJ. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonisation and protein-binding properties.Prog. Lipid Res.42, 463–478 (2003).
   PubMed Web of Science ®Google Scholar
• Aggarwal P , HallJB, McLelandCB, DobrovolskaiaMA, McNeilSE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.Adv. Drug Del. Rev.61, 428–437 (2009).
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA , AggarwalP, HallJB, McNeilS. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects of nanoparticle biodistribution.Mol. Pharmaceutics5, 487–495 (2008).
   PubMed Web of Science ®Google Scholar
• Kreuter J . Nanoparticulate systems for brain delivery of drugs.Adv. Drug Del. Rev.47, 65–81 (2001).
   PubMed Web of Science ®Google Scholar
• Alexis F , PridgenE, MolnarLK, FarokhzadOC. Factors affecting the clearance and biodistribution of polymeric nanoparticles.Mol. Pharmaceutics5, 505–515 (2008).
   PubMed Web of Science ®Google Scholar
• Li SD , HuangL. Pharmacokinetics and biodistribution of nanoparticles.Mol. Pharmaceutics5, 496–504 (2008).
   PubMed Web of Science ®Google Scholar
• Cho WS , ChoM, JeongJet al. Size-dependent kinetics of PEG-coated gold nanoparticles. Toxicol. App. Pharmacol. 245, 116–123 (2010).
   PubMed Web of Science ®Google Scholar
• He C , HuY, TangC, YinC. Effect of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles.Biomaterials31, 3657–3666 (2010).
   PubMed Web of Science ®Google Scholar
• Gaumet M , VargasA, GurnyR, DelieF. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters.Eur. J. Pharm. Biopharm.69, 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang L , ChanJM, GuFXet al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2, 1696–1702 (2008).
   PubMed Web of Science ®Google Scholar
• Ambruosi A , KhalaskyAS, YamamotoH, GelperinaSE, BegleyDJ, KreuterJ. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Targ.14, 97–105 (2006).
   PubMed Web of Science ®Google Scholar
• Besheer A , VogelJ, GlanzD, KresslerJ, GrothT, MaderK. Characterization of PLGA nanospheres stabilized with amphiphilic polymers: hydrophobically modified hydroxyethyl starch vs Pluronics.Mol. Pharmaceutics6, 407–415 (2009).
   PubMed Web of Science ®Google Scholar
• Sahagun G , MooreSA, HartMN. Permeability of neutral vs anionic dextrans in cultured brain microvascular endothelium.Am. J. Physiol.259, H162–H166 (1990).
   PubMed Web of Science ®Google Scholar
• Gaumet M , GurnyR, DelieF. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size.Eur. J. Pharm. Sci.36, 465–473 (2009).
   PubMed Web of Science ®Google Scholar
• Gao K , JiangX, Influence of particle size on transport of methotrexate across blood–brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm.310, 213–219 (2006).
   PubMed Web of Science ®Google Scholar
• Xu P , GullottiE, TongLet al. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol. Pharmaceutics 6, 190–201 (2009).
   PubMed Web of Science ®Google Scholar
• Mitragotri S , LahannJ. Physical approaches to biomaterial design.Nat. Mater.8, 15–23 (2009).
   PubMed Web of Science ®Google Scholar
• Doshi N , MitragotriS. Designer biomaterials for nanomedicine.Adv. Funct. Mater.19, 3843–3854 (2009).
   Web of Science ®Google Scholar
• Champion JA , MitragotriS. Role of target geometry in phagocytosis.Proc. Natl Acad. Sci. USA103, 4930–4934 (2006).
   PubMed Web of Science ®Google Scholar
• Hwang HY , KimIS, KwonIC, KimYH. Tumor targetability and antitumor effect of Docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.J. Contr. Rel.128, 23–31 (2008).
   PubMed Web of Science ®Google Scholar
• Sun X , RossinR, TurnerJLet al. An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules 6, 2541–2554 (2005).
   PubMedGoogle Scholar
• Bertholon I , VauthierC, LabarreD. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide.Pharm. Res.23, 1313–1323 (2006).
   PubMed Web of Science ®Google Scholar
• Costantino L , GandolfiF, TosiG, RivasiF, VandelliMA, ForniF. Peptide derivatized biodegradable nanoparticles able to cross the blood–brain barrier.J. Contr. Rel.108, 84–96 (2005).
   PubMed Web of Science ®Google Scholar
• Lu W , ZhangY, TanYZ, HuKL, JiangXG, FuSK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery.J. Contr. Rel.107, 428–448 (2005).
   PubMed Web of Science ®Google Scholar
• Hu K , LiJ, ShenYet al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J. Contr. Rel. 134, 55–61 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang Z , FengSS. In vitro investigation of poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialisys method for chemotherapy. Biomacromolecules7, 1139–1146 (2006).
   PubMed Web of Science ®Google Scholar
• Huang CY , LeeYD. Core-shell type of nanoparticles composed of poly[(n-butyl cyanoacrylate)-co-(2-octyl cyanoacrylate)] copolymers for drug delivery application: synthesis, characterization and in vivo degradation. Int. J. Pharm.325, 132–139 (2006).
   PubMedGoogle Scholar
• Vauthier C , DubernetC, FattalE, Pinto-AlphandaryH, CouvreurP. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications.Adv. Drug Del. Rev.55, 519–548 (2003).
   PubMed Web of Science ®Google Scholar
• Yoon SJ , KimSH, HaHJet al. Reduction of inflammatory reaction of poly(D,L-lactic-co-glycolic acid) using demineralised bone particles. Tissue Eng. Part A 14, 539–547 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson JM , ShiveMS. Biodegradation and biocompatibility of PLA and PLGA microspheres.Adv. Drug Del. Rev.28, 5–24 (1997).
   PubMed Web of Science ®Google Scholar
• Lherm C , MullerRH, PuisieuxF, CouvreurP. Alkylcyanoacrylate drug carriers II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length.Int. J. Pharm.84, 13–22 (1992).
   Web of Science ®Google Scholar
• Maurer-Jones MA , BantzKC, LoveSA, MarquisBJ, HaynesCL. Toxicity of therapeutic nanoparticles.Nanomedicine4, 219–241 (2009).
   PubMed Web of Science ®Google Scholar
• Xia T , KovochichM, LiongM, ZinkJI, NelAE. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways.ACS Nano2, 85–96 (2008).
   PubMed Web of Science ®Google Scholar
• Rao KS , ReddyMK, HorningJL, LabhasetwarV. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs.Biomaterials29, 4429–4438 (2008).
   PubMed Web of Science ®Google Scholar
• Jiskoot W , van Schie RMF, Carstens MG, Schellekens H. Immunological risk of injectable drug delivery systems. Pharm. Res.26, 1303–1314 (2009).
   PubMed Web of Science ®Google Scholar
• Bertholon I , VauthierC, LabarreC. Complement activation by core-shell poly(isobutylcyanoacrylate)-olysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide.Pharm. Res.23, 1313–1323 (2006).
   PubMed Web of Science ®Google Scholar
• Hamada I , HunterAC, SzebeniJ, MoghimiSM. Poly(ethylene glycol)generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.Molecular Immunol.46, 225–232 (2008).
   PubMedGoogle Scholar
• Lu W , WanJ, SheZ, JiangX, Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Contr. Rel.118, 38–53 (2007).
   PubMed Web of Science ®Google Scholar
• Simeonova M , ChorbadjievK, AntchevaM. Study of the effect of polybutylcyanoacrylate nanoparticles and their metabolites on the primary immune response in mice to sheep red blood cells.Biomaterials19, 2187–2193 (1998).
   PubMed Web of Science ®Google Scholar
• Arima Y , KawagoeM, TodaM, IwataH. Complement activation by polymers carrying dhydroxyl groups.ACS Appl. Mat. Interfaces1, 2400–2407 (2009).
   PubMed Web of Science ®Google Scholar
• Koziara JM , OhJJ, AkersWS, FerrarisSP, MumperRJ. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles.Pharm. Res.22, 1821–1828 (2005).
   PubMed Web of Science ®Google Scholar
• Kim D , El-ShallH, DennisD, MoreyT. Interaction of PLGA nanoparticles with human blood constituents.Colloids and Surf. B Biointerfaces40, 83–91 (2005).
   PubMed Web of Science ®Google Scholar
• Rajendran L , KnolkerHJ, SimonsK. Subcellular targeting strategies for drug design and delivery.Nature Rev. Drug Disc.9, 29–42 (2010).
   PubMed Web of Science ®Google Scholar
• Panyam J , ZhouWZ, PrabhaS, SahooSK, LabhasetwarV. Rapid endo-lysosomal escape of poly(D,L-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J.16, 1217–1226 (2002).
   PubMed Web of Science ®Google Scholar
• Lockman PR , KoziaraJM, MumperRJ, AllenDD. Nanoparticle surface charges alter blood–brain barrier integrity and permeability.J. Drug Target.12, 635–641 (2004).
   PubMed Web of Science ®Google Scholar
• Brigger I , MorizetJ, LaudaniLet al. Negative preclinical results with stealth nasnospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J. Contr. Rel. 100, 29–40 (2004).
   PubMed Web of Science ®Google Scholar
• Lundqvist M , StiglerJ, EliaG, LynchI, CedervallT, DawsonKA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts.Proc. Natl Acad. Sci. USA105, 14265–14270 (2008).
   PubMed Web of Science ®Google Scholar
• Langer K , SeegmullerE, ZimmerA, KreuterJ. Characterization of polybutylcyanoacrylate nanoparticles: I. Quatification of PBCA polymer and dextrans.Int. J. Pharm.110, 21–27 (1994).
   Google Scholar
• Batrakova EV , KabanovAV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers.J. Contr. Rel.130, 98–106 (2008).
   PubMed Web of Science ®Google Scholar
• Huang JG , SiLQ, JiangLL, FanZZ, QiuJ, LiG. Effect of Pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism.Int. J. Pharm.351–353 (2008)
   PubMedGoogle Scholar
• Sahoo SK , PanyamJ, PrabhaS, LabhasetwarV. Residual polyvinyl alcohol associated with poly(D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Contr. Rel.82, 105–114 (2002).
   PubMed Web of Science ®Google Scholar
• Sun W , XieC, WangH, HuY. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain.Biomaterials25, 3065–3071 (2004).
   PubMed Web of Science ®Google Scholar
• Breunig M , BauerS, GoepferichA. Polymers and nanoparticles: intelligent tools for intracellular targeting?Eur J. Pharm. Biopharm.68, 112–128 (2008).
   PubMed Web of Science ®Google Scholar
• Sahay G , AlakhovaDY, KabanovAV. Endocytosis of nanomedicines.J. Contr. Rel.145, 182–195 (2010).
   PubMed Web of Science ®Google Scholar
• Prabha S , ZhouWZ, PanyamJ, LabhasetwarV. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles.Int. J. Pharm.244, 105–115 (2002).
   PubMed Web of Science ®Google Scholar
• Zauner W , FarrowNA, HainesAM. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J. Contr. Rel.71, 39–51 (2001).
   PubMed Web of Science ®Google Scholar
• Torchilin VP . Rrecent approaches to intracellular delivery of drugs and DNA and organelle targeting.Annu. Rev. Biomed. Eng.8, 343–375 (2006).
   PubMed Web of Science ®Google Scholar
• Khalil IA , KogureK, AkitaH, HarashimaH. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery.Pharmacol. Rev.58, 32–45 (2006).
   PubMed Web of Science ®Google Scholar
• Tahara K , YamamotoH, KawashimaY. Cellular uptake mechanism and intracellular distribution of polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres for gene delivery. Eur. J. Pharm. Biopharm.75, 218–224 (2010).
   PubMed Web of Science ®Google Scholar
• Calvo P , GouritinB, ChacunHet al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18, 1157–1166 (2001).
   PubMed Web of Science ®Google Scholar
• Kim HR , GilS, AndrieuxKet al. Low density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell. Mol. Life Sci. 64, 356–364 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia E , AndrieuxK, GilSet al. A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int. J. Pharm. 298, 310–314 (2005).
   PubMedGoogle Scholar
• Lockman PR , OyewumiMO, KoziaraJM, RoderKE, MumperRJ, AllenDD. Brain uptake of thiamine-coated nanoparticles.J. Contr. Rel.93, 271–282 (2003).
   PubMed Web of Science ®Google Scholar
• Koziara J , LockmanPR, AllenDD, MumperRJ, In situ blood–brain barrier transport of nanoparticles. Pharm. Res.20, 1772–1778 (2003).
   PubMed Web of Science ®Google Scholar
• Lockman PR , KoziaraJ, RoderKE, PaulsonJ, AbbruscatoTJ, MumperRJ, AllenDD. In vivo and in vitro assessment of baseline blood–brain barrier parameters in the presence of novel nanoparticles. Pharm. Res.20, 705–713 (2003).
   PubMed Web of Science ®Google Scholar
• Menei P , DanielV, Montero-MeneiC, BrouillardM, Pouplard-BarthelaixA, BenoitJP. Biodegradation and brain tissue reaction of poly(D,L-lactide-co-glycolide) microspheres. Biomaterials14, 470–478 (1993).
   PubMed Web of Science ®Google Scholar
• Nicholas AP , McInnisC, GuptaKBet al. The fate of biodegradable microspheres injected into rat brain. Neurosci. Lett. 323, 85–88 (2002).
   PubMed Web of Science ®Google Scholar
• Chernenko T , MatthausC, MilaneL, QuinteroL, AmijiM, DiemM. Label-free raman spectral imaging of intracellular delivery and degradation of polymeric nanoparticle system.ACS Nano3, 3552–3558 (2009).
   PubMed Web of Science ®Google Scholar
• van Apeldoorn A , van Manen H, Bezemer J, de Bruijn, J, van Blitterswijk C, Otto C. Raman imaging of PLGA microspheres degradation inside macrophages. J. Am. Chem. Soc.126, 13226–13227 (2004).
   PubMed Web of Science ®Google Scholar
• Bazole DV , RopertC, HuvePet al. Body distribution of fully biodegradable [14C]poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13, 1093–1102 (1992).
   PubMedGoogle Scholar
• Muller RH , LhermC, HerbertJ, CouvreurP. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials11, 590–595 (1990).
   PubMed Web of Science ®Google Scholar
• Hasadsri L , KreuterJ, HattoriH, IwasakiT, GeorgeJM. Functional protein delivery into neurons using polymeric nanoparticles.J. Biol. Chem.284, 6972–6981 (2009).
   PubMed Web of Science ®Google Scholar
• Zensi A , BegleyD, PontikisCet al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Contr. Rel. 137, 78–86 (2009).
   PubMed Web of Science ®Google Scholar
• Cartiera M , JohnsonKM, RajendranV, CaplanMJ, SaltzmanWM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells.Biomaterials30, 2790–2798 (2009).
   PubMed Web of Science ®Google Scholar
• Hu YL , GaoJQ. Potential neurotoxicity of nanoparticles.Int. J. Pharm.394, 115–121 (2010).
   PubMed Web of Science ®Google Scholar
• Reis SA , WillemsenR, van Unen L, Hoogeveen AT, Oostra BA. Prospect of TAT-mediated protein therapy for fragile X syndrome. J. Mol. Histol.35, 389–395 (2004).
   PubMedGoogle Scholar
• Olivier JC . Drug transport to brain with targeted nanoparticles.NeuroRx2, 108–119 (2005).
   PubMedGoogle Scholar
• Sharma HS . Nanoneuroscience: emerging concepts on nanoneurotoxicity and nanoneuroprotection.Nanomedicine2, 753–758 (2007).
   PubMed Web of Science ®Google Scholar
• Sisson WB , OldendorfWH. Brain distribution spaces of mannitol-3H, inulin-14C, and Dextran-14C in the rat. Am. J. Physiol.221, 214–217 (1971).
   PubMedGoogle Scholar
• Alyautdin RN , ReichelA, LobenbergR, RamgeP, KreuterJ, BegleyDJ. Interaction of poly(butyl cyanoacrylate) nanoparticles with the blood–brain barrier in vivo and in vitro.J. Drug Targ.19, 209–221 (2001).
   Google Scholar
• Thole M , NobmannS, HuwylerJ, BartmannA, FrickerG. Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries.J. Drug Targ.10, 337–344 (2002).
   PubMed Web of Science ®Google Scholar
• Parikh T , BommanaMM, SquillanteE. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain.Eur. J. Pharm. Biopharm.74, 442–450 (2010).
   PubMed Web of Science ®Google Scholar
• Wang ZH , WangZY, SunCS, WangCY, JiangTY, WangSL. Trimethylated chitosan-conjugated PLGA nanoparticles fort the delivery of drugs to the brain.Biomaterials31, 908–915 (2010).
   PubMed Web of Science ®Google Scholar
• Kreuter J . Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain.J. Nanosci. Nanotech.4, 484–488 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia E , GilS, AndrieuxKet al. A relevant in vitro rat model for the evaluation of blood–brain barrier translocation of nanoparticles. CMLS Cell. Mol. Life Sci. 62, 1400–1408 (2005).
   PubMed Web of Science ®Google Scholar
• Hekmatara T , GelperinaS, VitaliV, Yang,SR, KreuterJ. Encapsulation of water-insoluble drugs in poly(butyl cyanoacrylate) nanoparticlesJ. Nanosci. Nanotech.9, 5091–5098 (2009).
   PubMed Web of Science ®Google Scholar
• Reimold I , DomkeD, BenderJ, SeyfriedCA, RadunzHE, FrickerG. Delivery of nanoparticles to the brain detected by fluorescence microscopy.Eur. J. Pharm. Biopharm.70, 627–632 (2008).
   PubMed Web of Science ®Google Scholar
• Weiss CK , KohnleMV, LandfesterKet al. The first step into the brain: uptake of NIO PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood–brain barrier permeation. ChemMedChem. 3, 1395–1403 (2008).
   PubMed Web of Science ®Google Scholar
• Olivier JC , FenartL, ChauvetR, PariatC, CecchelliR, CouetW. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.Pharm. Res.16, 1836–1842 (1999).
   PubMed Web of Science ®Google Scholar
• Kreuter J , RamgeP, PetrovVet al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20, 409–416 (2003).
   PubMed Web of Science ®Google Scholar
• Azmin MN , StuartJFB, FlorenceAT. The distribution and elimination of metotrexate in mouse blood and brain after concurrent administration of polysorbate 80.Cancer Chemother. Pharmacol.14, 238–242 (1985).
   PubMed Web of Science ®Google Scholar
• Sakane T , TanakaC, YamamotoAet al. The effect of polysorbate 80 on brain uptake and analgesic effect of D-kyothorphin. Int. J. Pharm. 57, 77–83 (1989).
   Google Scholar
• Schroeder U , SchroederH, SabelBA. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.Life Sci.66, 495–502 (2000)
   PubMed Web of Science ®Google Scholar
• Kurakhmaeva KB , DjindjikhashviliIA, PetrovVEet al. Brain targeting of Nerve Growth Factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Targ. 17, 564–574 (2009).
   PubMed Web of Science ®Google Scholar
• Michaelis K , HoffmannMM, DreisSet al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317, 1246–1253 (2006).
   PubMed Web of Science ®Google Scholar
• Kreuter J , HekmataraT, DreisS, VogelT, GelperinaS, LangerK, Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Contr. Rel.118, 54–58 (2007).
   PubMed Web of Science ®Google Scholar
• Lemarchand C , GrefR, PassiraniCet al. Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials 27, 108–118 (2006).
   PubMed Web of Science ®Google Scholar
• Goppert TM , MullerRH. Plasma protein adsorption on Tween 80 and Poloxamer 188-stabilized solid lipid nanoparticles.J. Drug Targ.11, 225–231 (2003).
   PubMed Web of Science ®Google Scholar
• Kreuter J . Use of nanoparticles for cerebral cancer.Tumor.94, 271–277 (2008).
   PubMed Web of Science ®Google Scholar
• Gelperina S , MaksimenkoO, KhalanskyAet al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm. 74, 157–163 (2010).
   PubMed Web of Science ®Google Scholar
• Petri B , BootzA., Khalansky A et al. Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Contr. Rel.117, 51–58 (2007).
   PubMed Web of Science ®Google Scholar
• Sun W , WangH, XieC, HuY, YangX, XuH. An attempt to directly trace polymeric nanoparticles in vivo with electron microscopy. J. Contr. Rel.115, 259–265 (2006).
   PubMedGoogle Scholar
• Santander-Ortega MJ , Jodar-ReyesAB, CsabaN, Bastos-GonzalezD, Ortega-VinuesaJL. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms.J. Colloid Interface Sci.302, 522–529 (2006).
   PubMed Web of Science ®Google Scholar
• Kim HR , AndrieuxK, GilSet al. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 8, 793–799 (2007).
   PubMed Web of Science ®Google Scholar
• Zara GP , CavalliR, BargoniA, FundaroA, VighettoD, GascoMR. Intravenous administration to rabbits of non-stealth and stealth Doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Targ.10, 327–335 (2002).
   PubMed Web of Science ®Google Scholar
• Ulbrich K , HekmataraE, KreuterJ. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB).Eur. J. Pharm. Biopharm.71, 251–256 (2009).
   PubMed Web of Science ®Google Scholar
• Aktas Y , YemisciM, AndrieuxK. et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconj. Chem.16, 1503–1511 (2005).
   PubMed Web of Science ®Google Scholar
• Karatas H , AktasY, Gursoy-OzdemirYet al. A nanomedicine transports a peptide Caspase-3 inhibitor across the blood–brain barrier and provides neuroprotection. J. Neurosci. 29, 13761–13769 (2009).
   PubMed Web of Science ®Google Scholar
• Vergoni AV , TosiG, TacchiR, VandelliMA, BeroliniA, CostantinoL. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine: NBM5, 369–377 (2009).
   PubMed Web of Science ®Google Scholar
• Brigger I , MorizetJ, AubertGet al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303, 928–936 (2002).
   PubMed Web of Science ®Google Scholar
• LeRay AM , VertM, GautierJC, BenoitJP. Fate of [14C]poly(D,L-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int. J. Pharm.106, 201–211 (1994).
   Google Scholar
• Lode J , FichtnerI, KreuterJ, BerndtA, DiederichsJE, ReszkaR. Influence of surface-modifying surfactants on the pharmacokinetic behaviour of 14C-poly(methylmethacrylate) nanoparticles in experimental tumor models. Pharm. Res.18, 1613–1619 (2001).
   PubMed Web of Science ®Google Scholar
• Dhuria SV , HansonLR, FreyWH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations.J. Pharm. Sci.99, 1654–1673 (2010).
   PubMed Web of Science ®Google Scholar
• Veldhorst-Janssen NML , FiddelersAAA, van der Ruy PHM, Neef C, Marcus MAE. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally. Clin. Ther.31, 2954–2987 (2009).
   PubMed Web of Science ®Google Scholar
• Mistry A , StolnikS, IllumL. Nanoparticles for direct nose to brain delivery of drugs.Int. J. Pharm.379, 146–157 (2009).
   PubMed Web of Science ®Google Scholar
• Ozsoy Y , GungorS, CevherE. Nasal delivery of high molecular weight drugs.Molecules14, 3754–3779 (2009).
   PubMed Web of Science ®Google Scholar
• Illum L . Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?J. Pharm. Sci.96, 473–483 (2007).
   PubMed Web of Science ®Google Scholar
• Schroeder U , SommerfeldP, SabelBA, Efficacy of oral dalargin-loaded nanoparticle delivery across the blood–brain barrier. Peptides19, 777–780 (1998).
   PubMed Web of Science ®Google Scholar
• Das D , LinSS. Double-coated poly(butylcyanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.J. Pharm. Sci.94, 1343–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Putney SD , BurkePA. Improving protein therapeutics with sustained-release formulations.Nat. Biotech.16, 153–157 (1998).
   PubMed Web of Science ®Google Scholar
• He W , JiangX, ZhangZR. Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin.J. Pharm. Sci.97, 2250–2259 (2008).
   PubMed Web of Science ®Google Scholar
• van de Weert M , HenninkWE, JiskootW. Protein instability in poly(lactic-co-glycolic acid) microparticles.Pharm. Res.17, 1159–1167 (2000).
   PubMed Web of Science ®Google Scholar
• Yang SX , YuanWE, JinT. Formulating protein therapeutics into particulate forms.Exp. Opin. Drug Del.6, 1123–1133 (2009).
   PubMed Web of Science ®Google Scholar

Patent

• Khrestchatisky M, Marion D, Yves M, Vlieghe P. 2937322 A1 20100423 (2010).
   Google Scholar

Website

• Bioalliance Pharma. www.bioalliancepharma.com
   Google Scholar